Tomahawk, WI 03/06/2014 (Basicsmedia) – Though ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) disappointed investors with its quarterly results, the company still has enough potential to bounce back. In fact, its shares have already bounced back and were trading at $55.89 at the end of trading on March 5, 2014.

The results:

Though ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) managed to improve revenues by 113% over the same period last year, it disappointed investors with its earnings. The company reported revenues of $42.2 million for the quarter as compared to $19.9 million declared for the same quarter last year. The company recorded revenues of $41.3 million from research and development on the back of the numerous collaborative agreements, against $17.9 million reported for the same period last year. Licensing and royalty fees accounted for $1 million in revenues.  Net loss widened to $24.3 million against $2.6 million for the fourth quarter of last year. This translates into a net loss of $0.21 per share reported for this quarter against net loss of $0.02 per share reported for the same period last year. Two main reasons were responsible for this. Lat year, the company had recognized a gain of $18.4 million in the fourth quarter related to an investment. The second reason was that research and development expenses increased by 34% to $57.4 million as the product pipeline expanded. In a way, this is good news as expenses were incurred towards later-stage trials as more treatments are progressing towards the commercialization stage.

The future prospects:

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) expects to start crucial phase 3 trials of at least three drugs by the end of this year as well as move 1 to the phase 2 stage in the same period. Operating expenses are expected to increase on this account. Kynamro continues to do well, according to an update by the company. The product is being handled by partner Genzyme. Though the company did not provide any figures on sales revenues, the fact that Genzyme is expanding its sales force, indicates the future potential. Kynamro is currently available in Argentine, Mexico as well as South Korea.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.